Bristol Myers Squibbvs.Pfizer
BMY vs PFE · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Pfizer is about 1.2× larger than Bristol Myers Squibb by market cap; year to date, Bristol Myers Squibb leads (+6.7% vs −2.9%).
Side by side
| BMY | PFE | |
|---|---|---|
| Market cap | $117B | $138B |
| Price | $57.58 | $24.17 |
| Today | −0.6% | −0.3% |
| Return YTD | +6.7% | −2.9% |
| Return 1Y | +18.7% | −6.2% |
| P/E | 19.6 | 18.5 |
| P/S | 2.4 | 2.2 |
| P/B | 5.8 | 1.5 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Bristol Myers SquibbBMY
American pharmaceutical group with strengths in oncology (Opdivo) and immunology, plus a neuroscience pipeline.
Full BMY profile →PfizerPFE
Large American pharmaceutical group with a broad portfolio in vaccines, oncology and internal medicine.
Full PFE profile →More comparisons in Big pharma
See where BMY and PFE sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →